Additionally, CLGN was found to be significantly upregulated in invasive breast cancer, chromophobe renal cell carcinoma, papillary renal cell carcinoma lung adenocarcinoma, lung squamous cell carcinoma, prostate adenocarcinoma, and uterine corpus endometrial carcinoma. This evidence concerns the gene CLGN and uterine corpus endometrial carcinoma.